Tagged with biosimilars,

USA Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA.   Advancements in biologic research and development have brought forth life-saving treatments for patients with cancer as well as such chronic…

Egypt Dr Wafik Bardissi, chairman and CEO of Minapharm, the only company to offer biosimilars in Egypt, highlights how the company has successfully developed biotech know-how by partnering with and acquiring German companies. He also emphasizes the need for more local manufacturing and improving biosimilar infrastructure in Egypt.   As Minapharm…

USA Chip Davis of the Association for Accessible Medicines argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements that the USA is currently negotiating with its neighbours.   An American president determined to seal a trade deal. A newly elected Democratic majority with…

France Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital sector, and its future growth strategies.   Generics companies need a wide portfolio to meet all of the generics needs…

Egypt Ahmed Mostafa, country manager of Amgen in Egypt and Iran, explains how the affiliate has been growing by providing end-to-end solutions. He also gives his take on the Egyptian government’s prioritization of healthcare and highlights that there are still improvements needed for bringing biosimilars to Egypt.     How would…

China China’s regulator approved a biosimilar version of Roche’s Rituxan this week, the first such drug ever to be given the green light in the country. With numerous other biological copycats of blockbuster drugs in development, potentially difficult times lie ahead for Roche and other Big Pharma firms in China.  …

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…

Spain María Jesús Lamas, director and César Hernández García, head of medicines for human use at the Spanish Agency of Medicine and Health Products (AEMPS), discuss the challenges impacting the evaluation and analysis of products today. Furthermore, they give insights into why Spain is a leading global clinical trials destination and…

Switzerland Roche announced strong Group sales growth of seven percent for 2018, partly driven by the launch of MS blockbuster Ocrevus, which CEO Severin Schwan has described as the most successful in the company’s history.   2018 was a good year for Roche. The Swiss-headquartered pharma giant saw seven percent overall…

China Dr Xu Ting, founder, chairman and CEO of Alphamab Oncology, shares his expert opinion on the recent regulatory and healthcare reforms in China, the expertise Alphamab Oncology has in protein engineering and their mission to become a highly differentiated oncology biotech company, and Alphamab’s dual China-US development strategy in support…

France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…